Optimizing ART With Novel HIV Agents

CCO Infectious Disease Podcast

محتوای ارائه شده توسط Clinical Care Options, LLC and Clinical Care Options. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط Clinical Care Options, LLC and Clinical Care Options یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal

4M ago 12:32

MP3•خانه قسمت

In this episode, Gregory Huhn, MD, MPHTM, presents a case study of a person with a long HIV treatment history, exploring when and how to consider agents with novel mechanisms of action.

Listen as he discusses:

The importance of engaging with patients to understand their perspectives and improve their satisfaction with their HIV care
Options in people with multiclass resistance
Studies of agents with novel mechanisms of action:
- BRIGHTE (fostemsavir)
- TMB-301/-311 (ibalizumab)
- CAPELLA (lenacapavir)

Faculty

Gregory Huhn, MD, MPHTM,
Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois

Follow along with the slides.
https://bit.ly/4fHmxg5

Get access to all of our new podcast episodes. Subscribe to the CCO Infectious Disease podcast on Apple Podcasts, Google Podcasts, or Spotify.

414 قسمت

#Science #Fitness #Biology #Higher Education #Podcasting Education #Medicine #Clinical Care Options, LLC #Clinical Care Options #HIV #On Covid19 #CME #Hepatitis B #Hbv #Infectious Disease Medical Education #Id Medical Education #Coronavirus #Hepatitis C #Hcv